AIM ImmunoTech (AIM) Stock Overview
An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AIM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AIM ImmunoTech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$36.00 |
| 52 Week Low | US$1.28 |
| Beta | 1.17 |
| 1 Month Change | -50.19% |
| 3 Month Change | -51.85% |
| 1 Year Change | -93.86% |
| 3 Year Change | -97.05% |
| 5 Year Change | -99.27% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| AIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.3% | 0.4% | -3.1% |
| 1Y | -93.9% | 16.6% | 11.2% |
Return vs Industry: AIM underperformed the US Biotechs industry which returned 16.6% over the past year.
Return vs Market: AIM underperformed the US Market which returned 11.2% over the past year.
Price Volatility
| AIM volatility | |
|---|---|
| AIM Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AIM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AIM's weekly volatility has decreased from 22% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 22 | Thomas Equels | aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
| AIM fundamental statistics | |
|---|---|
| Market cap | US$3.68m |
| Earnings (TTM) | -US$15.75m |
| Revenue (TTM) | US$112.00k |
Is AIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIM income statement (TTM) | |
|---|---|
| Revenue | US$112.00k |
| Cost of Revenue | US$95.00k |
| Gross Profit | US$17.00k |
| Other Expenses | US$15.77m |
| Earnings | -US$15.75m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.70 |
| Gross Margin | 15.18% |
| Net Profit Margin | -14,062.50% |
| Debt/Equity Ratio | -30.9% |
How did AIM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 23:45 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AIM ImmunoTech Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Ling Wang | Chardan Capital Markets, LLC |